Medical Cannabis for Spasticity — Switzerland 2026
Spasticity after SCI, stroke or in cerebral palsy often responds poorly to baclofen. Cannabis is an effective second-line — much cheaper for members.
TL;DR: Sativex is approved in Switzerland for MS spasticity, but used off-label in SCI, post-stroke spasticity and cerebral palsy. Observational evidence positive; RCTs mainly in MS. Starting dose 2–4 sprays/day, titrate to 12. CannabisClub members: 50 CHF flat instead of 190.
What the studies show
Hagenbach 2007 (RCT, n=25): THC capsules significantly reduced spasticity after spinal cord injury.
Grotenhermen 2003–2020 case series: cannabis effective in post-stroke spasticity when baclofen limited.
CP children: small observational studies with CBD-rich extracts show cramp reduction and sleep improvement.
Preparations & dosing
Sativex® 2–12 sprays/day — standard in central spasticity.
Dronabinol 2.5–10 mg twice daily as alternative.
CBD-rich oil 25–100 mg/day in children (specialist follow-up).
Vaporised flower for breakthrough symptoms.
Save as a CannabisClub member
Rehab centres rarely prescribe cannabis. External consult 190 CHF, member 50 CHF flat. Registration free.
FAQ
Is cannabis better than baclofen?
Not better, but complementary. Combination often needed — cannabis additionally targets pain and sleep.
What does membership save?
50 CHF instead of 190 CHF per consultation. Registration free.
Does insurance cover in non-MS spasticity?
Off-label with art. 71a HIO coverage possible if standard therapy fails.